Maxcyte SEC Filings

Form 8-K overview: On 25 June 2025, MaxCyte, Inc. ("the Company") filed a Current Report to disclose that it has applied to the London Stock Exchange to cancel admission of its common stock to trading on AIM. The filing designates the action as an "Other Event" under Item 8.01.

Key dates: The last day of AIM trading will be 25 June 2025, and the AIM delisting becomes effective at 7:00 a.m. U.K. time on 26 June 2025.

Continuing listing: The Company explicitly states that the AIM delisting "has no impact on the Company’s Nasdaq listing," and the shares will remain traded on the Nasdaq Global Select Market under ticker MXCT.

Additional disclosure items: No financial statements, earnings data, or major transactions are included. One exhibit (Ex. 104) accompanies the filing, containing the Inline XBRL cover page.

Implications disclosed: The filing is focused solely on the administrative change in listing status; it does not describe strategic rationale, cost implications, or future capital-markets plans. Investors trading on Nasdaq are unaffected according to the Company. U.K.-based investors will cease to have on-exchange access via AIM once the delisting takes effect.

MaxCyte, Inc. (MXCT) Form 4 – Insider equity grant

On 06/18/2025 non-employee director Rekha Hemrajani received her annual board compensation grant: (i) 29,210 restricted stock units (RSUs) and (ii) a stock option for 50,790 shares with a $2.11 exercise price, expiring 06/17/2035. The RSUs and options were issued under the company’s established Equity Grant Policy for outside directors.

The RSUs convert 1-for-1 into common shares and will vest in full on 06/18/2026, subject to continuous service. No cash was paid for the RSUs (code “A”; price $0). Following the grant, Hemrajani’s direct beneficial ownership increased to 50,577 common shares. No shares were sold or disposed of.

Because the grant is routine, the filing does not necessarily reflect incremental insider sentiment. Nonetheless, it maintains alignment between the director and shareholders and sets a strike price reference at $2.11; upside exists if MXCT trades above that level before 2035.

MaxCyte, Inc. (MXCT) – Form 4 insider filing

Non-employee director Stanley C. Erck reported two compensation-related equity grants dated 18 Jun 2025:

• 29,210 Restricted Stock Units (RSUs) acquired at $0 cost. Each RSU converts to one common share and is scheduled to vest on 18 Jun 2026, conditional on Mr. Erck’s continued board service.
• Stock option for 50,790 shares with an exercise price of $2.11 per share and an expiration date of 17 Jun 2035. The filing classifies the grant as an acquisition (“A”).

Post-transaction, Mr. Erck reports 298,328 common shares held directly. Option holdings now total 50,790 derivative securities.

The filing notes that the equity awards were made under the company’s Equity Grant Policy for non-employee directors. No open-market purchases or sales were disclosed, and there is no indication of a Rule 10b5-1 trading plan for this transaction.

Investor takeaway: The activity reflects routine annual board compensation, modestly increasing insider ownership without immediate cash outlay. It does not signal a change in fundamental outlook or corporate strategy.

MaxCyte, Inc. (ticker: MXCT) filed a Form 4 disclosing routine equity awards to non-employee director Richard Douglas on 18 June 2025. The filing reports two separate grants:

• Restricted Stock Units (RSUs): 29,210 shares of common stock at no cost. These RSUs will vest on 18 June 2026, contingent on Dr. Douglas remaining in continuous service.
• Stock Options: 50,790 options with an exercise price of $2.11 per share, expiring 17 June 2035. The option grant follows the company’s annual equity policy for outside directors.

Following the transaction, Dr. Douglas directly owns 150,577 shares of common stock and holds 50,790 options. The filing indicates the transaction was an automatic annual grant under MaxCyte’s non-employee director compensation plan, not an open-market purchase or sale. No shares were sold or disposed of, and no cash consideration was involved.

Because this is a scheduled board-compensation event rather than a discretionary trade, it generally signals neutral corporate governance housekeeping rather than a directional view on the stock. No other insider transactions, earnings data, or material corporate developments were reported in this filing.

MaxCyte, Inc. (MXCT) – Form 4 insider filing dated 06/23/2025

Independent director Cynthia Collins reported an annual equity grant under the company’s non-employee director compensation program. The grant consists of:

• 29,210 restricted stock units (RSUs) awarded on 06/18/2025 at no cost; each RSU converts into one common share upon vesting on 06/18/2026, assuming continuous board service.
• 50,790 stock options with an exercise price of $2.11 per share, expiring 06/17/2035. Vesting details beyond the standard one-year cliff for RSUs were not disclosed in the filing.

Following the grant, Collins’ direct beneficial ownership increased to 80,889 common shares, strengthening alignment between the director and shareholders. Because the RSUs and options were granted by the company rather than purchased on the open market, the transaction incurs no immediate cash outlay by the insider and does not provide new pricing insight to investors.

No sales, dispositions, or other derivative transactions were reported, and the filing does not contain financial performance data or forward-looking statements. Overall, this is a routine governance disclosure reflecting the company’s ongoing equity-based compensation practice for directors.